|
gptkbp:instanceOf
|
gptkb:drug
Bruton tyrosine kinase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2013
|
|
gptkbp:ATCCode
|
L01EL01
|
|
gptkbp:brand
|
gptkb:Imbruvica
|
|
gptkbp:CASNumber
|
936563-96-1
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:chemicalClass
|
aminopyrimidine
|
|
gptkbp:contraindication
|
hypersensitivity to ibrutinib
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
gptkb:Pharmacyclics
|
|
gptkbp:discoveredBy
|
gptkb:Pharmacyclics
|
|
gptkbp:eliminationHalfLife
|
4-6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:hasMolecularFormula
|
C25H24N6O2
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(N=C1)N2C=NC3=C2N=CN=C3C4=CC=CC=C4)C(=O)NC5=CC=CC=C5O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ibrutinib
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:KEGGID
|
gptkb:D09950
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits Bruton tyrosine kinase
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:patent
|
2006
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1873475
gptkb:DB09053
24821094
26333216
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:atrial_fibrillation
diarrhea
bleeding
infection
hypertension
|
|
gptkbp:UNII
|
IMT5049V5F9
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
gptkb:Waldenström's_macroglobulinemia
gptkb:chronic_graft_versus_host_disease
gptkb:marginal_zone_lymphoma
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:Waldenström's_macroglobulinemia
|
|
gptkbp:bfsLayer
|
6
|